FLGT News and Press, Fulgent Genetics Inc.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...

2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-06 11:36:47 ET Summary Today, we put diagnostic company Fulgent Genetics, Inc. back in the spotlight as sales growth is returning after navigating a "Covid Cliff." While the company is still losing money, the stock is trading for less than the net cash on Fulgent's balance...

Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was prese...

Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be p...

Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: F...

2024-05-03 11:53:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fulgent Genetics (NASDAQ: FLGT ) just reported results for the first quarter of 2024. Fulgent Genetics reported earnings per share of -1 cent. This was above the analyst e...

2024-05-03 11:43:08 ET Fulgent Genetics, Inc. (FLGT) Q1 2024 Earnings Call Transcript May 03, 2024, 08:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Conference Call Participants Dan Leona...

2024-05-03 07:07:45 ET More on Fulgent Genetics Fulgent Genetics: Buy Growth Ahead Below Liquidation Value Fulgent Genetics Non-GAAP EPS of $0.28 beats by $0.57, revenue of $70.51M beats by $4.19M Seeking Alpha’s Quant Rating on Fulgent Genetics Read...